Table 3.
Percentage of participants with 25(OH)D levels below a certain cut-off point at baseline and after vitamin D or placebo supplementation
| Group: | Total | Placebo | Vitamin D total | Vitamin D daily | Vitamin D weekly | Vitamin D monthly |
|---|---|---|---|---|---|---|
| 25(OH)D < 25 nmol/L | ||||||
| Baseline (t0) | 55.3 | 56.9 | 53.6 | 60.9 | 48.9 | 51.1 |
| 2 months (t1) | 30.1 | 57.8 | 2.9 | 2.2 | 0.0 | 6.8 |
| 4 months (t2) | 27.4 | 52.6 | 2.2 | 2.2 | 0.0 | 4.5 |
| 25(OH)D < 50 nmol/L | ||||||
| Baseline (t0) | 97.5 | 96.4 | 98.6 | 100.0 | 95.7 | 100.0 |
| 2 months (t1) | 65.4 | 94.8 | 36.5 | 26.1 | 19.1 | 65.9 |
| 4 months (t2) | 58.0 | 97.1 | 19.0 | 10.9 | 10.6 | 36.4 |
| 25(OH)D < 75 nmol/L | ||||||
| Baseline (t0) | 99.6 | 99.3 | 100.0 | 100.0 | 100.0 | 100.0 |
| 2 months (t1) | 95.2 | 99.3 | 91.2 | 87.0 | 89.4 | 97.7 |
| 4 months (t2) | 88.3 | 100.0 | 76.6 | 63.0 | 72.3 | 95.5 |